1889-78-7

Basic information

• Product Name: 2-BROMO-1-(4-CHLOROPHENYL)-2-PHENYLETHAN-1-ONE
• Synonyms: 2-BROMO-1-(4-CHLOROPHENYL)-2-PHENYLETHAN-1-ONE;2-BROMO-1-(4-CHLORO-PHENYL)-2-PHENYL-ETHANONE;2-Bromo-1-(4-chlorophenyl)-2-phenylethan-1-one, 95+%
• CAS NO: 1889-78-7
• Molecular Formula: C₁₄H₁₀BrClO
• Molecular Weight: 309.59
• Mol File: 1889-78-7.mol
• Article Data: 14

Chemical Properties

• Melting Point: 65 °C
• Boiling Point: 387.3°Cat760mmHg
• Flash Point: 188°C
• Appearance: /
• Density: 1.491g/cm³
• Vapor Pressure: 3.33E-06mmHg at 25°C
• Refractive Index: 1.625
• CAS DataBase Reference: 2-BROMO-1-(4-CHLOROPHENYL)-2-PHENYLETHAN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-1-(4-CHLOROPHENYL)-2-PHENYLETHAN-1-ONE(1889-78-7)
• EPA Substance Registry System: 2-BROMO-1-(4-CHLOROPHENYL)-2-PHENYLETHAN-1-ONE(1889-78-7)

Safety Data

• Hazard Codes: C:Corrosive
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 1889-78-7(Hazardous Substances Data)

Usage

General Description

2-BROMO-1-(4-CHLOROPHENYL)-2-PHENYLETHAN-1-ONE, also known as U-47700, is a synthetic opioid that has gained popularity as a recreational drug. It is classified as a designer drug and is structurally related to opioids such as fentanyl and AH-7921. U-47700 acts as a potent agonist at the mu-opioid receptor, producing effects similar to those of prescription opioids such as morphine and oxycodone. However, it also has a high potential for abuse and carries a significant risk of overdose and death. Due to these dangers, U-47700 has been classified as a Schedule I controlled substance in the United States and has been banned in several other countries.

InChI:InChI=1/C14H10BrClO/c15-13(10-4-2-1-3-5-10)14(17)11-6-8-12(16)9-7-11/h1-9,13H

Upstream product

• 1889-71-0 4'-chloro-2-phenylacetophenone 
• 108-90-7 chlorobenzene 
• 103-80-0 phenylacetyl chloride 
• 619-56-7 4-chlorobenzamide 
• 6921-34-2 benzylmagnesium chloride 
• 31233-66-6 1-(4-chlorophenyl)-2-phenylethanol 
• 74-11-3 para-chlorobenzoic acid 
• 100-39-0 benzyl bromide 
• 66985-46-4 (+/-)-2-(4-chlorophenyl)-2-(trimethylsiloxy)-acetonitrile 
• 104-88-1 4-chlorobenzaldehyde 

Downstream Products

• 88675-43-8 1-(4-Chloro-phenyl)-2-phenyl-2-piperidin-1-yl-ethanone 
• 88675-46-1 2-Azepan-1-yl-1-(4-chloro-phenyl)-2-phenyl-ethanone 
• 132818-45-2 6-(4-Chloro-phenyl)-7-phenyl-3-pyridin-4-yl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
• 108511-28-0 4-chlorobezoin phenylacetate 
• 132818-51-0 6-(4-Chloro-phenyl)-7-phenyl-3-p-tolyloxymethyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
• 22711-23-5 4-chlorobenzil 
• 807309-02-0 α-amino-4-chloro-deoxybenzoin 
• 132818-30-5 6-(4-Chloro-phenyl)-3-methyl-7-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
• 132818-39-4 6-(4-Chloro-phenyl)-7-phenyl-3-p-tolyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
• 132818-48-5 6-(4-Chloro-phenyl)-3-phenoxymethyl-7-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
• 132818-54-3 3-(4-Chloro-phenoxymethyl)-6-(4-chloro-phenyl)-7-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
• 161295-74-5 1-(4-Chloro-phenyl)-2-phenyl-2-(4-phenylamino-5-phenylsulfanylmethyl-4H-[1,2,4]triazol-3-ylsulfanyl)-ethanone 
• 161295-75-6 1-(4-Chloro-phenyl)-2-phenyl-2-(4-phenylamino-5-p-tolyloxymethyl-4H-[1,2,4]triazol-3-ylsulfanyl)-ethanone 
• 161295-76-7 1-(4-Chloro-phenyl)-2-[5-(2,4-dichloro-phenoxymethyl)-4-phenylamino-4H-[1,2,4]triazol-3-ylsulfanyl]-2-phenyl-ethanone 

Relevant articles and documents

Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors

Inhibition of the interactions of the tumor suppressor protein p53 with its negative regulators MDM2 in vitro and in vivo, representing a valuable therapeutic strategy for cancer treatment. The natural product chalcone exhibited moderate inhibitory activity against MDM2, thus based on the binding mode between chalcone and MDM2, a hit unsaturated pyrrolidone scaffold was obtained through virtual screening. Several unsaturated pyrrolidone derivatives were synthesized and biological evaluated. As a result, because the three critical hydrophobic pockets of MDM2 were occupied by the substituted-phenyl linked at the pyrrolidone fragment, compound 4 h demonstrated good binding affinity with the MDM2. Additionally, compound 4 h also showed excellent antitumor activity and selectivity, and no cytotoxicity against normal cells in vitro. The further antitumor mechanism studies were indicated that compound 4 h could successfully induce the activation of p53 and corresponding downstream p21 proteins, thus successfully causing HCT116 cell cycle arrest in the G1/M phase and apoptosis. Thus, the novel unsaturated pyrrolidone p53-MDM2 inhibitors could be developed as novel antitumor agents.

Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain

The emerging pharmacological target soluble epoxide hydrolase (sEH) is a bifunctional enzyme exhibiting two different catalytic activities that are located in two distinct domains. Although the physiological role of the C-terminal hydrolase domain is well-investigated, little is known about its phosphatase activity, located in the N-terminal phosphatase domain of sEH (sEH-P). Herein we report the discovery and optimization of the first inhibitor of human and rat sEH-P that is applicable in vivo. X-ray structure analysis of the sEH phosphatase domain complexed with an inhibitor provides insights in the molecular basis of small-molecule sEH-P inhibition and helps to rationalize the structure-activity relationships. 4-(4-(3,4-Dichlorophenyl)-5-phenyloxazol-2-yl)butanoic acid (22b, SWE101) has an excellent pharmacokinetic and pharmacodynamic profile in rats and enables the investigation of the physiological and pathophysiological role of sEH-P in vivo.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.